j********2
发帖数: 1895 | | p**********e
发帖数: 703 | | j********2
发帖数: 1895 | 3 好，听你的。
【在 p**********e 的大作中提到】
: I am not sure...
| p********e
发帖数: 1960 | 4 周末刚刚被某娱乐周刊评为2014的潜力股
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has been on the market for a little over a year.
Without an approval in hand, investors are rightfully discounting Orexigen.
Or put another way, Orexigen should have a similar value to Arena
Pharmaceuticals and VIVUS once investors are convinced that it has the same
potential as the other two.
An approval of Contrave looks highly likely after Orexigen successfully
completed all the FDA's requests from an earlier rejection. Orexigen has the
potential to double in value next year, which could make it one of 2014's
top health-care stocks.
【在 j********2 的大作中提到】
: RT
| c*******o
发帖数: 5387 | | t***l
发帖数: 3644 | 6 就是一阿斗不如allin $STXS
【在 c*******o 的大作中提到】
: 青龙老师说点评下。
|
|
